1 |
Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr 2006;25:711-5
DOI
ScienceOn
|
2 |
Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol: a summary of food and drug administration experience and a review of the literature. Arch Intern Med 1997; 157:1651-6
DOI
ScienceOn
|
3 |
Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 2006; 29:136-40
DOI
PUBMED
|
4 |
Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer 1999;86:1044-9
DOI
ScienceOn
|
5 |
Pascual Lopez A, Roqué i Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27:360-9
DOI
ScienceOn
|
6 |
Salvatori R. Adrenal insufficiency. JAMA 2005;294:2481-8
DOI
PUBMED
ScienceOn
|
7 |
Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y. A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 2002;38:1490-4
DOI
ScienceOn
|
8 |
Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor: correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983;32:1511-8
DOI
ScienceOn
|
9 |
Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis. Cancer Chemother Pharmacol 2003;52:482-6
DOI
ScienceOn
|
10 |
Loprinzi CL, Fonseca R, Jensen MD. Megestrol acetateinduced adrenal suppression. J Clin Oncol 1996;14:689
DOI
PUBMED
|